Table 1.

Baseline social and demographic characteristics of home-based and facility-based care groups

		Home-based care (n=859)	Facility-based care (n=594)
Female sex		625 (73%)	406 (68%)
Age (years)		37 (32–44)	38 (33–44)
Education
	No education	151 (18%)	83 (14%)
	Primary	484 (56%)	332 (56%)
	Secondary or tertiary	224 (26%)	179 (30%)
Marital status
	Married or cohabiting	300 (35%)	216 (36%)
	Widowed	351 (41%)	232 (39%)
	Divorced or separated	194 (23%)	137 (23%)
	Single	14 (2%)	9 (2%)
Median time taken to reach clinic (h)		1·0 (0·5–2·0)	1·25 (1·0–2·0)
Main form of transport to clinic
	Walking	36 (4%)	31 (5%)
	Minibus or car taxi	716 (83%)	479 (81%)
	Motorbike or bicycle taxi	66 (8%)	51 (8%)
	Other	41 (5%)	33 (5%)
WHO stage
	I	14 (2%)	6 (1%)
	II	384 (45%)	258 (43%)
	III	390 (45%)	283 (48%)
	IV	71 (8%)	47 (8%)
CD4-cell count (cells per μL)
	<50	272 (32%)	172 (29%)
	50–99	159 (19%)	73 (12%)
	100–149	170 (20%)	136 (23%)
	150–199	171 (20%)	168 (28%)
	≥200	87 (10%)	45 (8%)
	Median (IQR)	99 (34–162)	122 (30–167)
Plasma viral load copies per mL
	<1000	12 (1%)	9 (2%)
	1000–9999	21 (2%)	19 (3%)
	10 000–99 999	252 (29%)	202 (34%)
	100 000–999 999	514 (60%)	318 (54%)
	≥1 000 000	60 (7%)	46 (8%)
	Median (IQR)	173 000 (69 000–380 000)	151 700 (58 600–359 000)
Antiretroviral therapy prescription at enrolment
	Stavudine, lamivudine, nevirapine	401 (47%)	269 (45%)
	Stavudine, lamivudine, efavirenz	75 (9%)	61 (10%)
	Zidovudine, lamivudine, nevirapine	253 (29%)	188 (32%)
	Zidovudine, lamivudine, efavirenz	129 (15%)	75 (13%)
	Tenofovir, lamivudine and nevirapine	0	1 (<1%)
	Tenofovir, lamivudine and efavirenz	1 (<1%)	0

Data are n (%) or median (IQR).